---
title: Hemodynamic in Postreperfusion Period and Functional Recovery in Acute Ischemic Stroke Patients
nct_id: NCT05517109
overall_status: COMPLETED
phase: NA
sponsor: Northern State Medical University
study_type: INTERVENTIONAL
primary_condition: Acute Ischemic Stroke
countries: Russia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05517109.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05517109"
ct_last_update_post_date: 2024-10-30
last_seen_at: "2026-05-12T07:24:10.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Hemodynamic in Postreperfusion Period and Functional Recovery in Acute Ischemic Stroke Patients

**Official Title:** The Influence of Different Hemodynamic Parameters in First 24 Hours After Intravenous Thrombolysis on Acute Ischemic Stroke Outcomes: a Randomised Clinical Trial

**NCT ID:** [NCT05517109](https://clinicaltrials.gov/study/NCT05517109)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 90
- **Lead Sponsor:** Northern State Medical University
- **Conditions:** Acute Ischemic Stroke, Intracranial Hemorrhage
- **Start Date:** 2022-03-12
- **Completion Date:** 2024-08-31
- **CT.gov Last Update:** 2024-10-30

## Brief Summary

The investigators are suggtesting that lower goals of systolic blood pressure after intravenous thrombolysis may reduce the risk of hemorrhagic complications and improve functional outcomes after acute ischemic stroke.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion сriteria:

* ischemic stroke diagnosis
* performed intravenous thrombolysis (including "wake up stroke")
* systolic blood pressure \>140 mmHg
* informed consent or council of physician agreement

Exclusion criteria:

* absence of informed consent or council of physician agreement
* pregnancy
* patients participainting in other clinical trial in the last 90 days
* any absolute contraindications to intravenous thrombolysis

Сompletion criteria:

* failure to achieve hemodynamic goal for 20 minutes before the start of intravenous thrombolysis
* failure to achieve hemodynamic goal for 60 minutes in first 24 hours after intravenous thrombolysis
* relative arterial hypotension (SBP \<100 mmHg for 60 minutes in first 24 hours after intravenous thrombolysis)
* unfavorable effect development (e.g. seizures, angioedema)
* informed consent is retracted
```

## Arms

- **Control group. Standart care** (NO_INTERVENTION) — Standart hemodynamic goals: systolic blood pressure 160-185 mmHg in first 24 hours after intravenous thrombolysis
- **Systolic blood pressure ≤ 160 mmHg** (EXPERIMENTAL) — Lower hemodynamic goals: systolic blood pressure ≤ 160 mmHg in first 24 hours after intravenous thrombolysis

## Interventions

- **Hemodynamic goal including lower goal of systolic blood pressure** (OTHER) — Different hemodynamic goals in different study arms

## Primary Outcomes

- **Modified Rankin Scale score** _(time frame: 90 day after intravenous thrombolysis)_ — Fucntional outcome (Modified Rankin Scale) will be assesed by telephone interview. Score from 0 to 6. Higher scores mean a worse outcome.
- **Mortality rate** _(time frame: At 90 day after intravenous thrombolysis)_
- **Rate of symptomatic intracranial hemorrhage** _(time frame: 24 hours after intravenous thrombolysis)_ — Symptomatic intracranial hemorrhage (sICH) according to SITS-MOST study description of sICH
- **Rate of symptomatic intracranial hemorrhage** _(time frame: 7 days after intravenous thrombolysis)_ — Symptomatic intracranial hemorrhage (sICH) according to SITS-MOST study description of sICH

## Secondary Outcomes

- **Change in National Institutes of Health Stroke Scale (NIHSS)** _(time frame: at 28 day after intravenous thrombolysis)_
- **Rate of all Intracranial hemorrhage** _(time frame: 24 hours after intravenous thrombolysis)_
- **Rate of all Intracranial hemorrhage** _(time frame: 7 days after intravenous thrombolysis)_
- **Lengths of stay in ICU** _(time frame: at 90 day after intravenous thrombolysis)_
- **Lengths of stay in hospital** _(time frame: at 90 day after intravenous thrombolysis)_
- **Rate of acute kidney injury** _(time frame: 28 day after intravenous thrombolysis or at discharge)_

## Locations (1)

- City Hospital # 1 n.a. E.E. Volosevich, Arkhangelsk, Russia

## Recent Field Changes (last 30 days)

- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.city hospital # 1 n.a. e.e. volosevich|arkhangelsk||russia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05517109.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05517109*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*